Cardiovascular drug therapy in the elderly: benefits and challenges

Area of Science:

• Gerontology
• Cardiology
• Pharmacology

Background:

• Cardiovascular diseases (CVD) are prevalent in aging industrialized populations.
• Pharmacological therapy remains the primary treatment for CVD in older adults, despite advances in devices and surgery.
• Hypertension is a significant risk factor for major adverse cardiovascular events in the elderly.

Purpose of the Study:

• To review the pharmacological management of common cardiovascular diseases in older adults.
• To highlight the benefits and risks of specific drug classes in this demographic.
• To address challenges associated with polypharmacy and age-related physiological changes.

Main Methods:

• Review of clinical trial data and established guidelines for cardiovascular pharmacotherapy in the elderly.
• Analysis of drug efficacy and safety profiles for conditions like hypertension, coronary artery disease, heart failure, and atrial fibrillation.
• Consideration of factors influencing adherence and adverse drug events in older patients.

Main Results:

• Antihypertensive drugs reduce adverse outcomes in older adults with hypertension.
• Beta-blockers decrease mortality post-myocardial infarction across all age groups.
• Statins and antiplatelet agents are beneficial for coronary event prevention.
• ACE inhibitors and beta-blockers improve outcomes in chronic heart failure.
• Warfarin reduces stroke risk in atrial fibrillation but increases bleeding risk.

Conclusions:

• Pharmacological interventions are essential for managing CVD in the elderly.
• Specific drug classes demonstrate efficacy in reducing morbidity and mortality.
• Challenges in adherence and managing drug-related adverse events due to polypharmacy and comorbidities require careful attention.